Literature DB >> 16194203

Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation.

P A Lamont1, M V Ragni.   

Abstract

Although hemophilia A, a congenital disorder caused by defective or deficient factor VIII:C (FVIII), is cured by liver transplantation, the exact site of hepatic FVIII production is unknown. Further, while intracellular co-localization of FVIII and von Willebrand factor (VWF) is required for in vitro FVIII secretion, whether it is required for in vivo FVIII secretion is not known. An ideal setting to study this problem is in individuals with hemophilia A following liver transplantation, as their FVIII is synthesized primarily in hepatic, but not extrahepatic endothelial cells, while VWF is synthesized primarily in extrahepatic vascular endothelium. Following liver transplantation for end-stage liver disease, three hemophilic men showed VWF, but no FVIII response to (DDAVP) infusion. By contrast, both VWF and FVIII increased in a non-hemophilic transplant recipient after DDAVP. These findings support a model in which intracellular co-localization of FVIII and VWF is necessary for in vivo FVIII secretion after DDAVP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16194203     DOI: 10.1111/j.1538-7836.2005.01553.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  12 in total

Review 1.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

2.  Alternative strategies for gene therapy of hemophilia.

Authors:  Robert R Montgomery; Qizhen Shi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 3.  Platelets as delivery systems for disease treatments.

Authors:  Qizhen Shi; Robert R Montgomery
Journal:  Adv Drug Deliv Rev       Date:  2010-07-07       Impact factor: 15.470

4.  Murine coagulation factor VIII is synthesized in endothelial cells.

Authors:  Lesley A Everett; Audrey C A Cleuren; Rami N Khoriaty; David Ginsburg
Journal:  Blood       Date:  2014-04-09       Impact factor: 22.113

5.  Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice.

Authors:  Q Shi; E L Kuether; J A Schroeder; S A Fahs; R R Montgomery
Journal:  Haemophilia       Date:  2012-01-04       Impact factor: 4.287

6.  Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.

Authors:  Qizhen Shi; Scot A Fahs; Erin L Kuether; Brian C Cooley; Hartmut Weiler; Robert R Montgomery
Journal:  Blood       Date:  2010-07-06       Impact factor: 22.113

Review 7.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

8.  Mesenchymal stem cells contribute to endogenous FVIII:c production.

Authors:  Chad Sanada; Chung-Jung Kuo; Evan J Colletti; Melisa Soland; Saloomeh Mokhtari; Mary Ann Knovich; John Owen; Esmail D Zanjani; Christopher D Porada; Graça Almeida-Porada
Journal:  J Cell Physiol       Date:  2013-05       Impact factor: 6.384

9.  Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo.

Authors:  Junliang Pan; Thanh Theresa Dinh; Anusha Rajaraman; Mike Lee; Alexander Scholz; Cathrin J Czupalla; Helena Kiefel; Li Zhu; Lijun Xia; John Morser; Haiyan Jiang; Laura Santambrogio; Eugene C Butcher
Journal:  Blood       Date:  2016-05-12       Impact factor: 22.113

10.  A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.

Authors:  M V Ragni; R C Jankowitz; H L Chapman; E P Merricks; M T Kloos; A M Dillow; T C Nichols
Journal:  Haemophilia       Date:  2008-08-01       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.